Oric Pharmaceuticals Files 8-K
Ticker: ORIC · Form: 8-K · Filed: Feb 25, 2025 · CIK: 1796280
| Field | Detail |
|---|---|
| Company | Oric Pharmaceuticals, Inc. (ORIC) |
| Form Type | 8-K |
| Filed Date | Feb 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-K
Related Tickers: ORIC
TL;DR
Oric Pharma filed a routine 8-K, no major news.
AI Summary
Oric Pharmaceuticals, Inc. filed an 8-K on February 25, 2025, reporting other events and financial statements. The filing does not contain specific details about new material events, financial results, or significant corporate actions beyond the standard reporting requirements.
Why It Matters
This filing indicates Oric Pharmaceuticals is up-to-date with its regulatory reporting requirements, but it does not disclose any new material information that would immediately impact investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not contain any new material information that would suggest an immediate change in risk for the company.
Key Players & Entities
- Oric Pharmaceuticals, Inc. (company) — Registrant
- February 25, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-39269 (identifier) — Commission File Number
- 47-1787157 (identifier) — IRS Employer Identification No.
- 240 E. Grand Ave, 2nd Floor South San Francisco, CA 94080 (address) — Address of principal executive offices
- (650) 388-5600 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Oric Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of February 25, 2025.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on February 25, 2025.
In which U.S. state is Oric Pharmaceuticals, Inc. incorporated?
Oric Pharmaceuticals, Inc. is incorporated in Delaware.
What is the principal executive office address for Oric Pharmaceuticals, Inc.?
The principal executive office address is 240 E. Grand Ave, 2nd Floor, South San Francisco, CA 94080.
Does this 8-K filing disclose any new material financial results or significant corporate actions?
Based on the provided text, this 8-K filing is a standard report and does not appear to disclose any new material financial results or significant corporate actions beyond routine reporting.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 25, 2025 regarding Oric Pharmaceuticals, Inc. (ORIC).